A Review on Multi-layered Tablets: A way to control the drug release

ABSTRACT

Due to necessities their affordable manufacturing costs and simplicity of administration, especially in controlled-release applications, tablet dosage forms have traditionally been chosen over other formulations for oral medication delivery. Over monotherapy, combination therapy has a number of benefits. The pharmaceutical industry has grown more interested in recent years in creating dosage forms (monolithic, bilayer, or multi-layered tablets) that combine two or more Active Pharmaceutical Ingredients (API), improving patient convenience and compliance. The active pharmaceutical ingredient (API) is delivered from controlled-release tablets over an intended or prolonged period of time after oral administration. This may allow for a reduction in peak plasma concentrations and dose frequency, which enhances patient compliance while lowering the likelihood of unfavorable side effects. To transfer APIs into the body, conventional single-layered matrix tablets have been widely used. These traditional single-layered matrix tablets, however, have less than ideal delivery characteristics, such as non-linear drug release profiles that could result in more side effects. A multi-layered technology has recently been created to expand upon or replace the single-layered tablet's constraints. With the use of this technology, pharmaceutical businesses may have a better chance of creating new medications and improving their life cycle management. An overview of multi-layered tablets is provided in this article, with particular attention paid to manufacturing challenges, different tablet designs, and drug release profiles. This article covers the necessity for quality Multi-layered Tablet development and production, as well as the present state of the market.

Keywords: Multi-layered Tablet, controlled-release tablets, monolithic, matrix tablets